Azithromycin is an oral antibiotic with anti-inflammatory properties.
A Phase 3 trial showed CF patients with chronic Pseudomonas aeruginosa who took azithromycin experienced improved lung function and weight gain and decreased hospitalization rate. A follow-up trial showed that azithromycin decreased exacerbations in younger people with CF not infected with P. aeruginosa. Cystic Fibrosis Foundation Therapeutics (CFFT) is supporting a trial in infants in Australia.
In the US, the program is fully funded through Cystic Fibrosis Foundation Therapeutics (CFFT) and is being conducted within CFFT's Therapeutics Development Network.
Contact us about Azithromycin >